Janet Woodcock, acting FDA commissioner (Al Drago/Bloomberg via Getty Images)

FDA per­ma­nent­ly lifts in-per­son re­quire­ments for dis­pens­ing abor­tion pills

Since the pan­dem­ic be­gan, the FDA has al­lowed women to ac­cess the abor­tion drug mifepri­s­tone via the mail, mak­ing it eas­i­er for them and en­sur­ing that they don’t have to go to a clin­ic to re­ceive the pills.

The FDA’s tem­po­rary change be­came per­ma­nent on Thurs­day af­ter­noon, with the FDA an­nounc­ing that the REMS on mifepri­s­tone (brand name Mifeprex) and its gener­ic ver­sions must be mod­i­fied by re­mov­ing this in-per­son dis­pens­ing re­quire­ment.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.